-
Reduce recurrence, high popularity! "The Lancet" publishes Ma Jun team's adjuvant treatment plan for nasopharyngeal carcinoma
Time of Update: 2021-06-17
The results of a phase 3 randomized controlled trial showed that the addition of beat capecitabine to adjuvant therapy with radiotherapy and chemotherapy can significantly improve the survival rate of locally advanced nasopharyngeal carcinoma with controllable safety and will not affect the quality of life of patients .
-
Genome Biol & Sci Adv: The 3D structure of the genome may affect the progression of bladder cancer and childhood brain cancer
Time of Update: 2021-06-17
Recently, two articles were published in the international journal Genome Biology entitled "Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer" and the international journal Science Advances entitled "Epigenomic landscape and 3D genome structure in pediatric high-grade glioma" In the research report, scientists from Northwestern University and other institutions analyzed for the first time how the 3D structure of the patient’s body genome promotes the occurrence of bladder cancer and brain tumors in children .
-
Professor Wang Baocheng explores from top to bottom: Exploring "Vitality" in "Crisis"
Time of Update: 2021-06-17
From the end of the 20th century to the present, the clinical applications of recombinant cytokines, monoclonal antibody technology, immune cell therapy, tumor vaccines, oncolytic viruses, immune checkpoint inhibitors, etc.
-
How to standardize the application of new anti-tumor drugs for breast cancer?
Time of Update: 2021-06-17
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM) .
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group .
-
The high-risk metastatic prostate cancer is identified in the first time, and the patient is turned to safety!
Time of Update: 2021-06-17
60 nmol) /L), PSA value exceeds 2ng/ml, 3 consecutive increases and more than 50% increase from the baseline value, combined with the imaging examination results of no obvious metastasis on the whole body bone scan, resistance to non-metastatic castration according to authoritative guidelines The definition of prostate cancer (NM-CRPC) (Figure 4) can determine that the patient has entered a state of castration resistance and belongs to NM-CRPC .
-
The new benchmark K drug for precision immunization will add another major indication for first-line treatment
Time of Update: 2021-06-17
The KEYNOTE-177 study is the first head-to-head phase III clinical study to compare PD-1 monotherapy and standard chemotherapy for first-line MSI-H/dMMR metastatic colorectal cancer treatment with positive results .
-
ASCO Heavy Kidney Cancer: Immunotherapy may become a new standard for postoperative adjuvant treatment of high-risk renal cancer!
Time of Update: 2021-06-17
Methods: KEYNOTE-564 is a randomized, double-blind, phase III clinical trial designed to evaluate pembrolizumab versus placebo for adjuvant treatment of intermediate and high risks after nephrectomy (pT2, Gr4 or sarcoma-like, N0 M0; or pT3) , Any Gr, N0 M0), high-risk (pT4, any Gr, N0 M0; or pT any stage, any Gr, N+ M0) or M1 no evidence of disease (M1 NED) histologically confirmed efficacy of ccRCC patients .
-
2021ASCO express lenvatinib: multi-tumor evidence unfolds, demonstrating excellent efficacy
Time of Update: 2021-06-17
8LEAP-005: Lenvatinib + Pembrolizumab highlights the potential for the treatment of gastrointestinal tumors LEAP-005 (NCT03797326) is a phase II, multi-cohort, non-randomized, open-label study designed to evaluate lenvatinib+ The efficacy and safety of pembrolizumab in patients with advanced solid tumors who have previously received treatment, this time ASCO announced the LEAP-005 gastric cancer cohort (abstract number: 4030), colorectal cancer cohort (abstract number: 3564) and The results of the cholangiocarcinoma cohort (abstract number: 4080) .
-
EBEACOPP under the guidance of PET-2 can be used as a treatment option for advanced NLPHL
Time of Update: 2021-06-17
1 Research methods The study included patients 18-60 years old who received eBEACOPP intensive chemotherapy under the guidance of mid-term PET/CT examination results .
-
【Video】Professor Xu Ruihua's "Chinese Plan" for the treatment of nasopharyngeal cancer is internationally recognized
Time of Update: 2021-06-17
Professor Ruihua Xu’s report at the (ASCO) annual meeting is "JUPITER-02: A comparison of terreprizumab or placebo combined with gemcitabine and cisplatin in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
-
Full of dry goods!
Time of Update: 2021-06-17
▎The content team editor of WuXi AppTec recently, at an investor event held during the ASCO annual meeting, Roche gave a detailed introduction to the company's oncology R&D pipeline .
Today, WuXi AppTec's content team will share the highlights of this report with readers .
-
ASCO: Entering the harvest period ASCO 2021
Time of Update: 2021-06-17
On June 8, Yasheng presented two oral reports related to cell apoptosis products at the ASCO conference: about APG-2575 in patients with relapsed and refractory chronic lymphocytic leukemia (R/R CLL) and other hematological tumors Safety and efficacy, as well as the preliminary results of a phase II clinical study of APG-115 combined with pembrolizumab for the treatment of resistant unresectable/metastatic melanoma or advanced solid tumor patients with PD-1 inhibitors .
-
15 years of research on more than 300,000 women, the more such foods are eaten, the higher the risk of breast cancer
Time of Update: 2021-06-17
The research team said that after excluding factors including weight, drinking habits and exercise, the link between inflammatory diet and breast cancer risk still exists .
-
【Nature】Three heavy articles in a row: Cancer stem cells in the intestine have adverse effects on neighboring cells
Time of Update: 2021-06-17
Author: Yun Introduction: Malignant stem cells in the intestine secrete factors that promote the differentiation of neighboring stem cells, thereby helping those with cancer-promoting mutations to replace normal stem cells .
-
ASCO 2021: Gilead/Kite’s second commercial CAR-T product shows positive treatment results for new indications
Time of Update: 2021-06-17
Data from the key ZUMA-2 clinical trial showed that the overall response rate (ORR) of a single infusion of Tecartus in MCL patients was as high as 93%, and the complete response rate (CR) was 67% .
-
The Phase II clinical data of KN046 combined with chemotherapy in the first-line treatment of esophageal squamous cell carcinoma will be announced on ASCO 2021
Time of Update: 2021-06-17
June 7, 2021, Suzhou, China-Corning Jereh Biopharmaceuticals (stock code: 9966. HK) announced that it will announce PD-L1/CTLA in the form of a poster at the 2021 American Society of Clinical Oncolog
-
ASCO 2021 synchronizes 6 top medical journals, Ma Jun team’s nasopharyngeal cancer research published this morning
Time of Update: 2021-06-17
The significance of this study is that the authors confirmed for the first time in a phase 3 randomized controlled trial that capecitabine rhythm chemotherapy adjuvant treatment of high-risk locally advanced nasopharyngeal carcinoma can improve the survival rate of patients .
-
ASCO 2021: Fate's iPSC-derived NK cell clinical data is active
Time of Update: 2021-06-17
Recent popular reports from Yimaike ★ Invitation to the event 2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a year, an
-
2021 EHA indolent non-Hodgkin's lymphoma treatment new method exploration
Time of Update: 2021-06-17
Patients with recurrent iNHL who had no progression of disease after the last treatment with a treatment program containing rituximab (R) and stopped treatment for ≥12 months or were unwilling/unsuitable to receive chemotherapy were included in the study.
-
ASCO 2021: Allogene announces the latest clinical data of two allogeneic CD19 CAR-T drug treatments
Time of Update: 2021-06-17
Recommended article: GM CAR-T boss Cellectis once again expands its exclusive global license, the field is hot at home and abroad Yimai's new observation ALPHA (NCT03939026) study is to evaluate ALLO-501 in the treatment of R/R large B cell lymphoma (LBCL) ) Or a phase 1 study in adult patients with follicular lymphoma (FL) .
